BR0303570A - Gene de fator de crescimento de hepatócito hìbrido tendo eficiência de expressão elevada de dois heterotipos de fator de crescimento de hepatócito - Google Patents

Gene de fator de crescimento de hepatócito hìbrido tendo eficiência de expressão elevada de dois heterotipos de fator de crescimento de hepatócito

Info

Publication number
BR0303570A
BR0303570A BR0303570-0A BR0303570A BR0303570A BR 0303570 A BR0303570 A BR 0303570A BR 0303570 A BR0303570 A BR 0303570A BR 0303570 A BR0303570 A BR 0303570A
Authority
BR
Brazil
Prior art keywords
growth factor
hepatocyte growth
gene
heterotypes
high expression
Prior art date
Application number
BR0303570-0A
Other languages
English (en)
Other versions
BRPI0303570B8 (pt
BRPI0303570B1 (pt
Inventor
Jong-Mook Kim
Eun-Jin Park
Woong Hahn
Seung-Shin Yu
Sunyoung Kim
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of BR0303570A publication Critical patent/BR0303570A/pt
Publication of BRPI0303570B1 publication Critical patent/BRPI0303570B1/pt
Publication of BRPI0303570B8 publication Critical patent/BRPI0303570B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"GENE DE FATOR DE CRESCIMENTO DE HEPATóCITO HìBRIDO TENDO EFICIêNCIA DE EXPRESSãO ELEVADA DE DOIS HETEROTIPOS DE FATOR DE CRESCIMENTO DE HEPATóCITO". A presente invenção refere-se a um gene de fator de Crescimento de Hepatócito (HGF) híbrido que é preparado iserindo-se um intron inerente ou estrangeiro entre os exons 4 e 5 no cDNA de HGF, que tenha uma seq³ência de base da SEQ ID No: 2. O gene tem eficiência de expressão elevada e simultaneamente expressa dois heterotipos de HGF e dHGF (HGF de variante deletada). Além disso o gene pode ser empregado para tratar ou prevenir doenças do fígado ou isquêmicas.
BRPI0303570A 2002-03-20 2003-03-20 "construção de hgf, microrganismo transgênico, vetor e composição farmacêutico" BRPI0303570B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2002-0015074 2002-03-20
KR1020020015074A KR100562824B1 (ko) 2002-03-20 2002-03-20 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PCT/KR2003/000548 WO2003078568A2 (en) 2002-03-20 2003-03-20 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor

Publications (3)

Publication Number Publication Date
BR0303570A true BR0303570A (pt) 2005-07-19
BRPI0303570B1 BRPI0303570B1 (pt) 2018-04-24
BRPI0303570B8 BRPI0303570B8 (pt) 2021-05-25

Family

ID=28036130

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0303570A BRPI0303570B8 (pt) 2002-03-20 2003-03-20 "construção de hgf, microrganismo transgênico, vetor e composição farmacêutico"

Country Status (14)

Country Link
US (5) US7812146B2 (pt)
EP (1) EP1490492B1 (pt)
JP (1) JP4057537B2 (pt)
KR (1) KR100562824B1 (pt)
CN (1) CN100378219C (pt)
AT (1) ATE380826T1 (pt)
AU (1) AU2003210053A1 (pt)
BR (1) BRPI0303570B8 (pt)
DE (1) DE60318026T2 (pt)
DK (1) DK1490492T3 (pt)
ES (1) ES2298538T3 (pt)
HK (1) HK1080895A1 (pt)
PT (1) PT1490492E (pt)
WO (1) WO2003078568A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
AU2009234598C1 (en) * 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA
EP2216399A1 (en) * 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
CN102120047A (zh) * 2010-01-11 2011-07-13 上海优益绩国际贸易有限公司 血运重建基因药物靶向投递缓释支架
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
CN107073078B (zh) * 2014-09-26 2021-07-06 赫利世弥斯株式会社 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
WO2017135795A1 (ko) * 2016-02-04 2017-08-10 주식회사 에스엘바이젠 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도
EP3733855A4 (en) * 2017-12-29 2021-03-03 Helixmith Co., Ltd ADENO-ASSOCIATED VIRUS (AAV) VECTOR INCLUDING A HYBRID HGF GENE INTRODUCED INTO ITS BREAST
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
CN108611367B (zh) * 2018-04-24 2019-11-19 北京诺思兰德生物技术股份有限公司 一类通过质粒载体介导的基因治疗重组载体
US20190381138A1 (en) * 2018-05-17 2019-12-19 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
EP3823981A4 (en) * 2018-07-17 2022-04-06 Neuromyon Inc. TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
EP3823677A4 (en) 2018-07-19 2022-06-01 Helixmith Co., Ltd. FREEZE-DRIED PHARMACEUTICAL COMPOSITIONS INTENDED FOR NAKED-DNA GENE THERAPY
CN110747214B (zh) * 2019-03-13 2021-12-31 深圳市臻质医疗科技有限公司 DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法
KR20210035126A (ko) 2021-03-18 2021-03-31 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
WO2022211454A1 (ko) * 2021-03-29 2022-10-06 주식회사 헬릭스미스 샤르코-마리-투스병 예방 또는 치료용 약제학적 조성물
US20230212603A1 (en) * 2021-10-06 2023-07-06 G&P Bioscience Co., Ltd. Development of optimized recombinant expression construct

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
DK0539590T3 (da) * 1990-07-13 1999-10-11 Snow Brand Milk Products Co Ltd Plasmid indeholdende DNA, som koder for aminosyresekvensen af TCF-II, en transformeret celle og fremstilling af et fysiolog
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
DE69634567T2 (de) * 1995-08-29 2006-02-16 Anges Mg Inc., Toyonaka Ein medikament,das hgf gen enthält
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP2002515065A (ja) 1997-05-06 2002-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物
JPH11246433A (ja) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
AU766238B2 (en) 1998-03-09 2003-10-09 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
AU5065599A (en) * 1998-08-05 2000-02-28 Sumitomo Pharmaceuticals Company, Limited Preparations for the administration of hepatocyte growth factor
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
EP1225921A1 (en) 1999-11-05 2002-07-31 The Regents of the University of California TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY
CN1142272C (zh) * 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
DE60134021D1 (de) * 2000-06-27 2008-06-26 Anges Mg Inc Pharmazeutische zubereitungen zur angiogenese-therapie
US20020172663A1 (en) * 2001-01-23 2002-11-21 Maria Palasis Localized myocardial injection method for treating ischemic myocardium
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
WO2006121532A2 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
AU2009234598C1 (en) * 2008-04-09 2012-08-23 Viromed Co., Ltd. Lyophilized DNA formulations for enhanced expression of plasmid DNA

Also Published As

Publication number Publication date
US7745174B2 (en) 2010-06-29
JP2005520512A (ja) 2005-07-14
US20120010273A1 (en) 2012-01-12
USRE48404E1 (en) 2021-01-26
US20050079581A1 (en) 2005-04-14
DE60318026T2 (de) 2008-11-20
CN100378219C (zh) 2008-04-02
AU2003210053A8 (en) 2003-09-29
US20100105878A1 (en) 2010-04-29
US7812146B2 (en) 2010-10-12
HK1080895A1 (en) 2006-05-04
KR20030075718A (ko) 2003-09-26
CN1643149A (zh) 2005-07-20
JP4057537B2 (ja) 2008-03-05
DK1490492T3 (da) 2008-03-17
WO2003078568A2 (en) 2003-09-25
AU2003210053A1 (en) 2003-09-29
DE60318026D1 (de) 2008-01-24
US7838505B2 (en) 2010-11-23
US8338385B2 (en) 2012-12-25
EP1490492A4 (en) 2006-05-31
KR100562824B1 (ko) 2006-03-23
EP1490492A2 (en) 2004-12-29
US20090131350A1 (en) 2009-05-21
EP1490492B1 (en) 2007-12-12
WO2003078568A3 (en) 2003-11-27
BRPI0303570B8 (pt) 2021-05-25
PT1490492E (pt) 2008-03-25
ES2298538T3 (es) 2008-05-16
BRPI0303570B1 (pt) 2018-04-24
ATE380826T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
HK1080895A1 (en) Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
EA200401591A1 (ru) Керамические аноды и способ их изготовления
DE69731834D1 (de) Agouti verwandtes gen
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE60129805D1 (de) Genetisches testverfahren zur bestimmung des risikos der entwicklung von pouchitis
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
EP1734827A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ABERRANT MICROSATELLITARY EXPANSION
DE60228136D1 (de) Cytokin-proteinfamilie
ATE260296T1 (de) Anti-gefrier proteine, deren herstellung und verwendung
ATE307205T1 (de) Gefrorenes lebensmittel
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE60126864D1 (de) Verfahren zur Herstellung von (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione und Analoge
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
EP1321473A4 (en) METHOD FOR PREVENTING FROZEN ACTIVITY OF PROTEIN INDUCED BY FREEZING, AND USE OF POLYPEPTIDE IN THE PRODUCTION OF PREVENTIVE AGENT AGAINST SUCH ACTIVITY
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
DE60323052D1 (de) Zwei gonadotropin-freisetzende hormone und methode zur isolierung
DE59915086D1 (de) Rekombinante l-n-carbamoylase aus arthrobacter aurescens, verfahren zur herstellung von l-aminosäuren mittels dieser
DK1194158T3 (da) Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning
DE50006815D1 (de) Verfahren zur herstellung antitumoraler th1-zellen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 20/03/2023